N-{3-[4-(4-cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl}acetamide HCl | 740873-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-{3-[4-(4-cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl}acetamide HCl
• 英文别名: Naluzotan hydrochloride；N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide;hydrochloride
• CAS: 740873-82-9
• 化学式: C₂₃H₃₈N₄O₃S*2ClH
• 分子量: 523.568
• InChiKey: QBACIVGQRFVOBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.47
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  90.1
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-[3-[4-[4-[(环己基甲基磺酰基)氨基]丁基]哌嗪-1-基]苯基]乙酰胺 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 N-{3-[4-(4-cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl}acetamide HCl
  参考文献：
  名称：

  [EN] NEW ARYLPIPERAZINYL COMPOUNDS
  [FR] NOUVEAUX COMPOSES D'ARYLPIPERAZINYLE

  摘要：

  公开号：

  WO2004069794A3

文献信息

• Arylpiperazinyl compounds
  申请人：——

  公开号：US20040220192A1

  公开（公告）日：2004-11-04

  The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂或拮抗剂。公开了由公式I表示的新型芳基哌嗪磺酰胺化合物及其合成和用于治疗直接或间接由5-HT受体介导的疾病的用途。这些疾病包括中枢神经系统疾病，如广泛性焦虑症、ADD/ADHD、神经损伤、中风和偏头痛。还包括制备方法、新型中间体和其制药盐。
• Arylpiperazinyl Compounds
  申请人：Dhanoa S. Dale

  公开号：US20080027066A1

  公开（公告）日：2008-01-31

  The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂或拮抗剂。公开了由式I表示的新型芳基哌嗪磺酰胺化合物及其合成和用途，用于治疗包括直接或间接通过5-HT受体介导的疾病。这些疾病包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。还包括制备方法、新型中间体和药物盐。
• NEW ARYLPIPERAZINYL COMPOUNDS
  申请人：Predix Pharmaceuticals Holdings, Inc.

  公开号：EP1592425A2

  公开（公告）日：2005-11-09
• EP1592425A4
  申请人：——

  公开号：EP1592425A4

  公开（公告）日：2007-01-24
• US7153858B2
  申请人：——

  公开号：US7153858B2

  公开（公告）日：2006-12-26